RxDoctor Payments Data

Karen Watkins Plunkett, MD

Neurology · Grenada, MSNPI 1902919756

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.8% of the total.

$3,868in general payments, 2019–2025

Across 225 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$667
  • Novartis$559
  • Lilly USA, LLC$292
  • Eisai Inc.$199
  • Johnson & Johnson$138
  • plus $784 from 15 others

What the payments were for

  • Food & beverage$3,75897%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,868 in reported general payments places this provider in the 60th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$94,605
Medicare patients
314
Services billed
864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a12$98,337
UbrelvyUbrogepant15$36,452
Aimovig AutoinjectorErenumab-Aooe17$36,002
Emgality PenGalcanezumab-Gnlm18$31,946
LamictalLamotrigine12$18,972
XcopriCenobamate14$15,581
Rufinamide12$5,322
Memantine Hcl157$2,899
Memantine Hcl ErMemantine Hcl22$2,708
Levetiracetam72$2,586
Rivastigmine15$1,731
Gabapentin48$1,097
Donepezil Hcl116$1,066
Ropinirole Hcl59$1,060
Phenytoin Sodium Extended27$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$667$36,45215 claims
SK Life Science, Inc.Xcopri$121$15,58114 claims
Upsher-smith Laboratories LLCTopiramate$22$21345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 neurology providers in Mississippi.

Other neurology in Grenada

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →